Read about how researchers across the world are using QIAGEN Digital Insights solutions to accelerate their work in a variety of applications
Powerful insights help innovate, integrate and translate scientific results into impactful discoveries. Many noteworthy papers cite QIAGEN Digital Insights solutions and demonstrate how our tools help drive research insights and discoveries. These papers use QIAGEN Ingenuity Pathway Analysis (IPA), QIAGEN CLC and/or QIAGEN OmicSoft to help drive success. The QIAGEN Digital Insights portfolio encompasses a comprehensive, easy-to-use toolbox that ensures continuity in NGS workflow. Here, we have curated a selection of just a few recent papers to offer a sense of the diversity of the research for which QIAGEN Digital Insights solutions makes a difference.
First author: Bruno Hernáez
Check out this fascinating research from Dr. B. Hernáez and colleagues at the Autonomous University of Madrid who investigate the ability of native cells to detect viral infection. Read how the team uses QIAGEN IPA to understand the role of DNA-sensing pathways in cellular detection and protection against acute lethal viral infection. Read their full paper here.
3D curvature-instructed endothelial flow response and tissue vascularization
First author: Christian Mandrycky
Can the way blood flows in three dimensions affect cellular transcriptomics? Read this exciting research by Dr. C. Mandrycky and colleagues at the University of Washington who try to understand the effects of vascularization in a three-dimensional space. Learn how the team uses QIAGEN IPA to understand the single-cell transcriptomic changes that occur in endothelial cells when a spiral blood flow is applied. Read the full article here.
First author: Alyssa M. Flores
Discover this fascinating nanotechnology research out of Stanford University by Dr. A Flores and colleagues, who investigate phagocytosis as a therapy for clearing atherosclerotic plaques. See how the team uses QIAGEN IPA to show the effectiveness of drug dispensing nanoparticles in reducing pro-inflammatory pathways and potentially preventing atherosclerosis. Read their full paper here.
First author: Aymeric Silvin
Don’t miss this critical research by Dr. A. Silvin and colleagues from Inserm, who investigate biomarkers to predict the development of severe COVID-19 in patients. Delve into their study, and learn how QIAGEN IPA supports their understanding of how the accumulation of calprotectin and abnormal monocytes may help differentiate between severe and mild COVID-19. Read the full article here.
First author: Jack Major
Immunologists at the Francis Crick Institute investigate the harmful effects of excessive cytokine signaling during respiratory viral infection. Learn how they use QIAGEN IPA to investigate how IFN signaling interferes with lung repair during influenza/viral recovery. Read their full paper in Science here.
First author: Yingyue Zhou
Are we a step closer to understanding Alzheimer’s risk? Learn about fascinating research by Y. Zhou and colleagues at Washington University in St. Louis who study the role of microglia receptor TREM2 in Alzheimer’s pathogenesis. See how they use QIAGEN IPA to investigate how TREM2 increases AD risk and activation of disease-associated microglia. Read the full article here.
First Author: Ana Campos Codo
Discover why diabetic patients may be more at risk of developing severe COVID-19. Researchers at the Universidade Estadual de Campinas investigate the role of elevated blood glucose levels in inducing cytokine storms in severe COVID-19 patients. See how the team uses QIAGEN IPA to investigate how the HIF-1α axis in monocytes causes T-cell dysfunction and reduces epithelial cell survival. Read their full paper here.
QIAGEN CLC Genomics
First author: Yong Zhang
Should we be looking for new mutations in SARS-CoV-2 that make it more virulent? Researchers from the Chinese Center for Disease Control and Prevention perform genomic characterization of SARS-CoV-2 identified in a reemerging outbreak in China. Discover how they use QIAGEN CLC Genomics Workbench to help trace the source of the virus in this second outbreak in Beijing’s Xinfadi market. Read their full article here.
First author: Jing Yang
Crucial coronavirus research from the Chinese Academy of Sciences looking into the re-emergence of the SARS-CoV-2 virus in China. Discover how they use the nanopore and MiSeq system together with QIAGEN CLC Genomics Workbench to trace the source of the virus in this second outbreak in Beijing. Get the full article here.
First author: B. Rapun-Araiz
High-impact research by B. Rapun-Araiz and colleagues at Universidad Publica de Navarra in Spain who investigate the targets of two-component signal transduction systems (TCSs) in bacteria. See how they use QIAGEN CLC Genomics Workbench to map the complete TCS regulon in Staphylococcus aureus. Read the full paper here.
First author: Andrea J. Pruijssers
Excellent research by A. Pruijssers and colleagues at Vanderbilt University who study how Remdesivir inhibits SARS-CoV-2 in human lung cells. See how they use QIAGEN CLC Main Workbench to help investigate the efficacy of Remdesivir against SARS-CoV-2 in vitro and in vivo. Read the full article here.
First author: Ryo Higuchi-Sanabria
Exciting research from the Howard Hughes Medical Institute, where researchers investigate the role of lysosomes in amino acid recycling. Learn how they use QIAGEN CLC Genomics Workbench to understand how reduced lysine and arginine can cause increased sensitivity to proteotoxic stress in the endoplasmic reticulum (ER). Read the full paper here.
First author: Nicole Ziegler
Could HDAC inhibitors serve as epigenetic therapy? Intriguing research by Dr. N. Ziegler and colleagues at Sanofi investigate the therapeutic potential of class IIa HDAC inhibition. See how the team uses QIAGEN OmicSoft Studio to understand the consequences of this inhibition, which has a limited effect on glucose metabolism but causes severe side effects in the kidney and spleen. Read the full paper here.
First Author: Marina Stolina
Can we develop biomarkers to predict cardiometabolic syndrome using the obese ZSF1 rat model? Read this paper to learn how researchers at Amgen use QIAGEN IPA and OmicSoft Studio to characterize the obese ZSF1 rat model to develop biomarkers that predict cardiometabolic syndrome, a global health issue, to better understand the cardioprotective effects of GDF15. Read the full article here.
First author: Birandra K. Sinha
Fascinating research by Dr. B Sinha and colleagues at the National Institute of Environmental Health Sciences (NIEHA), who investigate the mechanisms of topotecan-induced cell death in human breast cancer cells. Learn how the team uses QIAGEN OmicSoft Studio to understand the role of reactive oxygen species in inducing tumor cell killing. Read the full paper here.
First author: Johanna Escoubet
Exciting discovery by J. Escoubet and colleagues at Sanofi who study a new diacylglycerol lipase involved in weight gain regulation. Learn how they use QIAGEN ArrayStudio to understand how inhibiting ABHD11 helps reduce intestinal fat absorption. Read the full paper here.
To request information on the QIAGEN Digital Insight solutions, contact firstname.lastname@example.org.